Journal issues > Issue 1, February 2017 > MicroRNA as predictive biomarkers for drug resistance and sensitivity in colorectal cancer

MicroRNA as predictive biomarkers for drug resistance and sensitivity in colorectal cancer

By: G. Li PhD, A. Cavazzoni PhD, E. Giovannetti MD, PhD, M. A. Barbera MD, G. Frega MD, G. Biasco MD, I. Garajová MD, PhD

SUMMARY

Despite significant improvement in anticancer treatment options, many patients are resistant or develop secondary resistance to anticancer agents, highlighting the necessity for seeking novel predictive markers for drug resistance. Piling evidence has identified miRNAs as predictive markers for resistance/sensitivity to chemotherapy and anti-VEGF/anti-EGFR monoclonal antibody therapy in colorectal cancer patients. In this review, we summarise the current knowledge of the role of miRNAs as possible response predictors to current anticancer treatments for metastatic colorectal cancer patients.

(BELG J MED ONCOL 2017;11(1):18–25)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top